Dyne Therapeutics (DYN)
Market Price (4/25/2026): $18.28 | Market Cap: $2.7 BilSector: Health Care | Industry: Biotechnology
Dyne Therapeutics (DYN)
Market Price (4/25/2026): $18.28Market Cap: $2.7 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35% Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -68% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.44, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -468 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% Key risksDYN key risks include [1] potential clinical trial failures or regulatory delays for its lead candidates in DMD and DM1 and [2] intense competition from established pharmaceutical companies like Sarepta Therapeutics and Roche. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -68% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.44, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -468 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| Key risksDYN key risks include [1] potential clinical trial failures or regulatory delays for its lead candidates in DMD and DM1 and [2] intense competition from established pharmaceutical companies like Sarepta Therapeutics and Roche. |
Qualitative Assessment
AI Analysis | Feedback
1. Consistent Positive Clinical Progress and Defined Regulatory Pathways: Dyne Therapeutics has maintained a steady positive trajectory in its clinical pipeline, particularly for its lead programs. In December 2025, the company reported positive topline results from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy (DMD), demonstrating a statistically significant change to 5.46% of normal in muscle content-adjusted dystrophin expression at six months, representing a 7-fold change from baseline. Dyne remains on track for a U.S. Accelerated Approval submission for z-rostudirsen in Q2 2026, with a potential launch projected for Q1 2027. Similarly, enrollment for the registrational expansion cohort of z-basivarsen in myotonic dystrophy type 1 (DM1) is expected to be completed in Q2 2026, with data planned for Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in early Q3 2027. This consistent advancement of clinical milestones and clear regulatory timelines provided a strong underlying support for the stock, preventing significant declines.
2. Robust Financial Position and Extended Cash Runway: As of December 31, 2025, Dyne Therapeutics reported a strong cash, cash equivalents, and marketable securities balance of $1.1 billion. This substantial financial backing is projected to fund the company's operations into the first quarter of 2028. This extended cash runway significantly de-risks the company's ability to continue its clinical development programs without immediate concerns about financing, contributing to investor confidence and helping to stabilize the stock price.
Show more
Stock Movement Drivers
Fundamental Drivers
The -6.6% change in DYN stock from 12/31/2025 to 4/24/2026 was primarily driven by a -4.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.56 | 18.26 | -6.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 142 | 148 | -4.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| DYN | -6.6% | |
| Market (SPY) | 4.2% | 45.9% |
| Sector (XLV) | -6.9% | 40.4% |
Fundamental Drivers
The 44.3% change in DYN stock from 9/30/2025 to 4/24/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.65 | 18.26 | 44.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 114 | 148 | -23.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| DYN | 44.3% | |
| Market (SPY) | 7.0% | 35.8% |
| Sector (XLV) | 4.0% | 25.7% |
Fundamental Drivers
The 74.6% change in DYN stock from 3/31/2025 to 4/24/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.46 | 18.26 | 74.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 102 | 148 | -31.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| DYN | 74.6% | |
| Market (SPY) | 28.1% | 36.0% |
| Sector (XLV) | 0.1% | 33.0% |
Fundamental Drivers
The 58.5% change in DYN stock from 3/31/2023 to 4/24/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.52 | 18.26 | 58.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 53 | 148 | -64.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/24/2026| Return | Correlation | |
|---|---|---|
| DYN | 58.5% | |
| Market (SPY) | 79.8% | 31.0% |
| Sector (XLV) | 16.6% | 26.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DYN Return | -43% | -3% | 15% | 77% | -17% | -3% | -10% |
| Peers Return | -7% | 32% | 41% | -1% | 2% | 9% | 90% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 4% | 89% |
Monthly Win Rates [3] | |||||||
| DYN Win Rate | 17% | 50% | 42% | 67% | 42% | 50% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 67% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DYN Max Drawdown | -43% | -63% | -43% | -2% | -71% | -25% | |
| Peers Max Drawdown | -25% | 0% | -2% | -3% | -23% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ALPS, DFTX, EIKN, GENB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/24/2026 (YTD)
How Low Can It Go
| Event | DYN | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -85.1% | -25.4% |
| % Gain to Breakeven | 572.0% | 34.1% |
| Time to Breakeven | 713 days | 464 days |
Compare to VRTX, ALPS, DFTX, EIKN, GENB
In The Past
Dyne Therapeutics's stock fell -85.1% during the 2022 Inflation Shock from a high on 1/13/2021. A -85.1% loss requires a 572.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Dyne Therapeutics (DYN)
AI Analysis | Feedback
Here are a few analogies for Dyne Therapeutics (DYN):
Vertex Pharmaceuticals for muscle diseases.
Moderna, but applying a specialized drug delivery platform to genetic muscle diseases.
AI Analysis | Feedback
- Therapeutics for Myotonic Dystrophy Type 1 (DM1): Drug candidates in development to treat myotonic dystrophy type 1, a genetically driven muscle disease.
- Therapeutics for Duchenne Muscular Dystrophy (DMD): Drug candidates in development to treat Duchenne muscular dystrophy, a severe muscle-wasting disease.
- Therapeutics for Facioscapulohumeral Dystrophy (FSHD): Drug candidates in development to treat facioscapulohumeral dystrophy, a progressive muscle weakness and wasting condition.
- Therapeutics for Rare Skeletal Muscle Diseases: Programs focused on developing treatments for various other rare diseases affecting skeletal muscles.
- Therapeutics for Cardiac and Metabolic Muscle Diseases: Programs focused on developing treatments for muscle diseases impacting cardiac function and metabolism.
AI Analysis | Feedback
As a biotechnology company focused on advancing therapeutics for genetically driven muscle diseases, Dyne Therapeutics (DYN) is primarily engaged in research, development, and clinical trials for its drug candidates. At this stage, the company does not have major customers in the traditional sense, as its therapeutic products are still in development and have not yet been commercialized for sale to individuals or other companies.
AI Analysis | Feedback
nullAI Analysis | Feedback
John Cox
President and Chief Executive OfficerJohn Cox was appointed President and Chief Executive Officer of Dyne Therapeutics on March 25, 2024. Prior to joining Dyne, he served as CEO of Bioverativ Inc., a spin-off from Biogen Inc., which was subsequently acquired by Sanofi in 2018. Mr. Cox also held the CEO position at Repertoire Immune Medicines and its predecessor, Torque Therapeutics. Over a 14-year tenure at Biogen, he held various senior roles, including Executive Vice President of Global Commercial & Technical Operations, and was instrumental in orchestrating the spin-out of Biogen's hematology business to form Bioverativ. He brings extensive experience in rare disease commercialization and global operations to Dyne.
Erick J. Lucera
Chief Financial OfficerErick J. Lucera was appointed Chief Financial Officer of Dyne Therapeutics, effective March 31, 2025. He brings over three decades of financial, operational, and investment experience in the life science industry. Before joining Dyne, Mr. Lucera served as CFO at Editas Medicine. Previously, he was CFO of AVEO Pharmaceuticals, where he played a key role in its transition from a clinical-stage company to commercialization and its acquisition by LG Chem. His background also includes executive positions as CFO, treasurer, and secretary at Valeritas and Viventia Bio, and Vice President of Corporate Development at Aratana Therapeutics. Mr. Lucera also spent 15 years in investment management as a healthcare analyst.
Ranjan (Ron) Batra, Ph.D.
Chief Scientific OfficerRanjan (Ron) Batra, Ph.D., was appointed Chief Scientific Officer of Dyne Therapeutics in April 2025. Dr. Batra joined Dyne from Lexeo Therapeutics, where he was the Vice President of Research and Translation. He previously served as Senior Vice President of R&D at LocanaBio, where he advanced RNA-targeted therapies for rare disorders, including Duchenne muscular dystrophy and myotonic dystrophy. Dr. Batra is recognized as a leading expert in RNA biology and therapeutics.
Oxana Beskrovnaya, Ph.D.
Chief Innovation OfficerOxana Beskrovnaya, Ph.D., transitioned to the role of Chief Innovation Officer at Dyne Therapeutics, effective April 28, 2025, where she is responsible for driving the company's comprehensive innovation strategy. Prior to this, she served as Dyne's Chief Scientific Officer, a position she was appointed to in June 2021 after serving as Senior Vice President, Head of Research since January 2020. Before joining Dyne, Dr. Beskrovnaya was Head of Musculoskeletal and Renal Research in Sanofi's rare disease and neurological unit, where she advanced a pipeline of drug candidates.
Vikram (Vik) Ranade, PhD
Chief Business OfficerVikram (Vik) Ranade, PhD, was appointed Chief Business Officer of Dyne Therapeutics in April 2025. In this role, Dr. Ranade leads business development, corporate strategy, and strategic partnerships for the company, supporting its late-stage clinical and commercialization plans.
AI Analysis | Feedback
The key risks for Dyne Therapeutics (symbol: DYN), a biotechnology company focused on developing therapeutics for genetically driven muscle diseases, are primarily associated with the inherent uncertainties of drug development and the financial demands of a clinical-stage company.
- Clinical Trial Failures: Dyne Therapeutics' success is heavily dependent on positive data from its ongoing and future clinical trials for lead candidates like DYNE-251 for Duchenne muscular dystrophy (DMD) and DYNE-101 for myotonic dystrophy type 1 (DM1). Adverse or unclear results, unexpected safety issues, or failure to meet efficacy endpoints could significantly impact the company's valuation and prospects.
- Regulatory Delays and Challenges: The process for obtaining regulatory approvals from agencies like the FDA is complex and often unpredictable. Delays in receiving approval, or even in filing for approval, for its product candidates could deplete Dyne's cash reserves faster than anticipated. The interpretation of clinical trial data by regulatory authorities and the acceptance of Dyne's clinical programs also present significant uncertainties.
- Financial Risks and Need for Additional Funding: As a clinical-stage biotechnology company, Dyne Therapeutics currently generates no revenue and incurs substantial operating losses due to extensive research and development costs. While the company has cash reserves, there is a continuous need for significant external funding to sustain its operations and advance its pipeline. If clinical trial timelines shift or expenses increase, future fundraising efforts through equity offerings or debt financing could lead to the dilution of existing shareholders' stakes.
AI Analysis | Feedback
Direct Competition with Advanced Therapies for Shared Indications: Avidity Biosciences (AVID) is developing antibody-oligonucleotide conjugates (AOCs) for genetically driven muscle diseases, a therapeutic approach conceptually similar to Dyne's FORCE platform. Avidity's lead candidate, AOC 1044, is in Phase 3 for Myotonic Dystrophy Type 1 (DM1), a key target for Dyne, whose DYNE-101 is in Phase 1/2. Avidity also has AOC 1020 in Phase 1/2 for Facioscapulohumeral Dystrophy (FSHD), another of Dyne's target indications. This advanced clinical progress by a direct competitor using a similar platform poses a significant threat to Dyne's market position and development timeline for these diseases.AI Analysis | Feedback
Dyne Therapeutics (NASDAQ: DYN) is focused on developing therapeutics for genetically driven muscle diseases, with programs targeting Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Dystrophy (FSHD).
Myotonic Dystrophy Type 1 (DM1)
The global addressable market for Myotonic Dystrophy Type 1 (DM1) is projected to experience significant growth. In 2024, the market was valued at approximately USD 1,550 million and is expected to reach USD 3,204 million by 2032, demonstrating a Compound Annual Growth Rate (CAGR) of 9.5% over the forecast period. Another estimate places the global market at USD 874.39 million in 2023, with a projection to reach around USD 2,789.35 million by 2033, growing at a CAGR of 12.3%. North America accounts for a substantial portion of the global DM1 market, representing 35% of the market share. The U.S. alone had approximately 54,068 diagnosed prevalent cases of Myotonic Dystrophy in 2023, accounting for 51% of the total cases across the seven major markets (7MM: U.S., Germany, Spain, Italy, France, UK, and Japan). DM1 is considered a large, unaddressed market with no approved disease-modifying therapies currently available.
Duchenne Muscular Dystrophy (DMD)
The global Duchenne Muscular Dystrophy (DMD) drug market reached an estimated value of USD 2.3 billion in 2023 and is anticipated to grow to USD 5.5 billion by 2032, with a CAGR of 9.96% from 2024 to 2032. Other reports indicate the global market size for DMD drugs was valued at USD 3.2 billion in 2023 and is projected to reach USD 8.6 billion by 2032, at a CAGR of 11.6%. Another source estimates the global DMD drugs market size at USD 3.47 billion in 2023, with a projection to reach USD 9.91 billion by 2030, exhibiting a higher CAGR of 16.8% from 2024 to 2030. In 2023, the DMD market size across the 7MM was approximately USD 2,150 million. The United States represents the largest market for DMD drugs within the 7MM, with an estimated market size of around USD 1,900 million. North America held the largest revenue share, 45.0%, in the global Duchenne muscular dystrophy drugs market in 2023.
Facioscapulohumeral Dystrophy (FSHD)
The 7 major Facioscapulohumeral Muscular Dystrophy (FSHD) markets had a value of USD 32.2 million in 2024 and are expected to reach USD 61.4 million by 2035, with a CAGR of 6.12% during 2025-2035. A global market report indicates the FSHD market was valued at USD 210 million in 2024 and is projected to reach USD 482 million by 2034, expanding at a CAGR of 8.6% during this period. The United States holds the largest market share for Facioscapulohumeral Muscular Dystrophy, accounting for approximately 80% of the market compared to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. Conversely, Europe is noted for having the largest patient pool and also representing the largest market for FSHD treatment.
AI Analysis | Feedback
Dyne Therapeutics (DYN), a biotechnology company focused on genetically driven muscle diseases, is poised for future revenue growth over the next 2-3 years through the advancement and potential commercialization of its pipeline products. Key drivers include:
- Commercialization of Z-rostudirsen (DYNE-251) for Duchenne Muscular Dystrophy (DMD): Dyne Therapeutics is on track for a Biologics License Application (BLA) filing for U.S. Accelerated Approval of z-rostudirsen in the second quarter of 2026, with a potential commercial launch anticipated in the first quarter of 2027. This represents the most immediate potential revenue stream for the company.
- Commercialization of Z-basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1): The company is progressing with its registrational expansion cohort for z-basivarsen, with data expected in mid-2026 to support a potential U.S. Accelerated Approval BLA submission in late 2026. A pivotal Phase 3 HARMONIA trial for z-basivarsen was initiated in March 2026, with a potential commercial launch projected for 2027-2028.
- Expansion of the Duchenne Muscular Dystrophy (DMD) Franchise: Beyond z-rostudirsen, Dyne is developing additional preclinical programs targeting other exons (e.g., 53, 45, 44, and 55) for DMD. This expansion could significantly broaden the addressable patient population for their DMD therapies by tripling the market to 4,000-5,000 patients, leveraging the validated FORCE platform.
- Advancement of Pipeline Programs for Other Genetically Driven Muscle Diseases: Dyne's FORCE platform is being utilized to advance preclinical programs for other rare neuromuscular disorders, including facioscapulohumeral muscular dystrophy (FSHD) with DYNE-302 and Pompe disease with DYNE-401. Positive preclinical data for DYNE-401 in Pompe disease was highlighted in February 2026, indicating future potential and diversification of their therapeutic portfolio. Continued progress in these programs through clinical development stages would be a driver of future revenue growth.
AI Analysis | Feedback
```htmlShare Issuance
- In December 2025, Dyne Therapeutics closed an upsized underwritten public offering, selling 21,827,549 shares of common stock at $18.44 per share, resulting in gross proceeds of approximately $402.5 million.
- In July 2025, the company completed a public offering that generated approximately $230 million in gross proceeds.
Inbound Investments
- In June 2025, Dyne Therapeutics secured a $275 million non-dilutive senior secured term loan facility from Hercules Capital, Inc., with an initial tranche of $100 million funded at closing.
- The term loan facility includes additional tranches totaling up to $115 million, available upon achieving specific clinical, regulatory, and commercial milestones, and a final tranche of up to $60 million subject to approval.
- As of December 2025, institutional investors collectively increased their stake in Dyne Therapeutics to 159.84 million shares, representing 138.0% of the company, reflecting a 10.54% quarter-over-quarter increase.
Capital Expenditures
- Capital expenditures in a recent quarter (Q3 2025) totaled approximately -$19.19 million.
- Dyne expects its existing cash, cash equivalents, and marketable securities, including proceeds from recent offerings and the term loan, to fund its operating expenses and capital expenditure requirements into the third quarter of 2027. This cash runway was further extended into Q1 2028 based on year-end 2025 cash of $1.1 billion.
- The primary focus of capital expenditures is to advance its pipeline, particularly late-stage clinical trials for DYNE-101 and DYNE-251, and to build out commercial infrastructure for potential product launches in 2027-2028.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Dyne Therapeutics Earnings Notes | 12/29/2026 | |
| Dyne Therapeutics (DYN) Operating Cash Flow Comparison | 08/08/2025 | |
| Dyne Therapeutics (DYN) Net Income Comparison | 08/08/2025 | |
| Dyne Therapeutics (DYN) Debt Comparison | 08/08/2025 | |
| Dyne Therapeutics (DYN) Tax Expense Comparison | 08/08/2025 | |
| Dyne Therapeutics (DYN) Operating Income Comparison | 08/08/2025 | |
| Dyne Therapeutics (DYN) Revenue Comparison | 08/08/2025 | |
| Dyne Therapeutics (DYN) EBITDA Comparison | 08/08/2025 | |
| ARTICLES | ||
| DYN Stock Down -31% after 8-Day Loss Streak | 06/24/2025 | |
| Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run? | 05/21/2024 |
Trade Ideas
Select ideas related to DYN.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.53 |
| Mkt Cap | 55.9 |
| Rev LTM | 0 |
| Op Inc LTM | -166 |
| FCF LTM | -132 |
| FCF 3Y Avg | -92 |
| CFO LTM | -132 |
| CFO 3Y Avg | -92 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.9% |
| Rev Chg 3Y Avg | 10.4% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | -36.1% |
| Op Inc Chg 3Y Avg | -37.4% |
| Op Mgn LTM | 37.9% |
| Op Mgn 3Y Avg | 24.7% |
| QoQ Delta Op Mgn LTM | 38.7% |
| CFO/Rev LTM | 30.3% |
| CFO/Rev 3Y Avg | 20.5% |
| FCF/Rev LTM | 26.6% |
| FCF/Rev 3Y Avg | 17.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 55.9 |
| P/S | 9.1 |
| P/Op Inc | 9.1 |
| P/EBIT | 8.7 |
| P/E | 10.8 |
| P/CFO | 11.7 |
| Total Yield | -6.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -7.5% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.6% |
| 3M Rtn | -3.0% |
| 6M Rtn | 1.6% |
| 12M Rtn | -2.0% |
| 3Y Rtn | 15.4% |
| 1M Excs Rtn | -13.3% |
| 3M Excs Rtn | -6.6% |
| 6M Excs Rtn | -5.9% |
| 12M Excs Rtn | -35.3% |
| 3Y Excs Rtn | -56.4% |
Price Behavior
| Market Price | $18.26 | |
| Market Cap ($ Bil) | 2.7 | |
| First Trading Date | 09/17/2020 | |
| Distance from 52W High | -24.8% | |
| 50 Days | 200 Days | |
| DMA Price | $17.64 | $16.33 |
| DMA Trend | up | up |
| Distance from DMA | 3.5% | 11.8% |
| 3M | 1YR | |
| Volatility | 71.4% | 86.0% |
| Downside Capture | 1.99 | 1.41 |
| Upside Capture | 275.81 | 236.18 |
| Correlation (SPY) | 52.7% | 35.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.24 | 2.96 | 2.21 | 2.55 | 1.66 | 1.72 |
| Up Beta | 2.42 | 1.81 | 3.80 | 5.08 | 1.49 | 1.49 |
| Down Beta | 4.27 | 3.37 | 2.25 | 2.14 | 1.40 | 1.89 |
| Up Capture | 969% | 475% | 226% | 401% | 430% | 758% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 10 | 21 | 29 | 60 | 124 | 370 |
| Down Capture | 177% | 196% | 159% | 142% | 145% | 111% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 12 | 21 | 33 | 65 | 127 | 374 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DYN | |
|---|---|---|---|---|
| DYN | 69.7% | 85.9% | 0.98 | - |
| Sector ETF (XLV) | 7.7% | 15.8% | 0.28 | 27.8% |
| Equity (SPY) | 34.0% | 12.6% | 2.05 | 34.9% |
| Gold (GLD) | 42.9% | 27.2% | 1.29 | -0.5% |
| Commodities (DBC) | 46.4% | 18.0% | 1.97 | -7.7% |
| Real Estate (VNQ) | 14.2% | 13.3% | 0.74 | 17.2% |
| Bitcoin (BTCUSD) | -16.6% | 42.1% | -0.32 | 17.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DYN | |
|---|---|---|---|---|
| DYN | 0.4% | 79.3% | 0.35 | - |
| Sector ETF (XLV) | 5.1% | 14.6% | 0.17 | 27.8% |
| Equity (SPY) | 12.7% | 17.1% | 0.58 | 33.4% |
| Gold (GLD) | 21.2% | 17.8% | 0.97 | 1.9% |
| Commodities (DBC) | 14.5% | 19.1% | 0.62 | -2.3% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 27.3% |
| Bitcoin (BTCUSD) | 7.0% | 56.3% | 0.34 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DYN | |
|---|---|---|---|---|
| DYN | -2.7% | 78.9% | 0.29 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 26.1% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 32.4% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | 0.9% |
| Commodities (DBC) | 10.1% | 17.8% | 0.47 | -1.6% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 26.9% |
| Bitcoin (BTCUSD) | 68.3% | 66.9% | 1.07 | 16.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/2/2026 | 3.4% | -4.9% | 9.4% |
| 11/5/2025 | -12.9% | -11.0% | 6.2% |
| 7/28/2025 | -1.2% | 10.1% | 43.7% |
| 5/8/2025 | 20.2% | 24.5% | 56.4% |
| 2/27/2025 | -4.5% | -11.7% | -14.4% |
| 11/12/2024 | 4.3% | 4.3% | -2.3% |
| 3/5/2024 | -6.6% | -7.8% | 3.8% |
| 10/30/2023 | 10.6% | 24.3% | 57.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 8 | 8 |
| # Negative | 7 | 10 | 10 |
| Median Positive | 3.4% | 7.2% | 15.2% |
| Median Negative | -4.5% | -8.2% | -5.9% |
| Max Positive | 20.2% | 24.5% | 57.1% |
| Max Negative | -12.9% | -11.7% | -15.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/02/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 07/28/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 10/30/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/02/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/2/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2028 Cash Runway | 2,028 | 0 | Affirmed | Guidance: 2,028 for 2028 | |||
Prior: Q4 2025 Earnings Reported 1/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2028 Cash Runway | |||||||
| 2025 Cash Position | 1.10 Bil | ||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.